Practice guidelines for lipid-based amphotericin B in stem cell transplant recipients

Annals of Pharmacotherapy

Volumn 35, Issue 2, 2001, Pages 206-216

  Quilitz, R E ^a   Arnold, A D ^a   Briones, G R ^a   Dix, S P ^a   Ippoliti, C ^a   Kennedy, L D ^a   Lucich, J L ^a   Mehta, J ^a   Peters, B G ^a   Tice, D S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Amphotericin; Aspergillus; Bone marrow transplant; Fungal infection; Lipid

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX;

ARTICLE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; HUMAN; IMMUNE DEFICIENCY; MORBIDITY; MORTALITY; MYCOSIS; NEPHROTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0035140150     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10041     Document Type: Article

References (54)

1. Fungal infections after bone marrow transplant
2. Fungal infections in bone marrow transplant patients
3. Candida infections in bone marrow transplant recipients
4. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation
5. Aspergillus infections in bone marrow transplant recipients
6. Amphotericin B: 30 years of clinical experience
7. The clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis
8. Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice
9. Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations?
10. Lipid formulations of amphotericin B: Clinical efficacy and toxicities
11. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: A preliminary study
12. Treatment of hepatosplenic candidiasis with liposomal-amphotericin B
13. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant
14. Improved safety and efficacy of AmBisome (liposomal amphotericin B) compared with amphotericin B in the empirical treatment of febrile neutropenic patients undergoing bone marrow transplantation
15. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies
16. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: A single-centre experience of 133 episodes in 116 patients
17. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses
18. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients
19. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis
20. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases
21. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
22. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis
23. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia
24. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses
25. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery, system, ABCD, and a conventional formulation to rats
26. Amphotericin B lipid complex (ABLC): A molecular rationale for the attenuation of amphotericin B related toxicities
27. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits
28. Tissue distribution of amphotericin B lipid complex in laboratory animals
29. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents
30. Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats
31. Liposome disposition in vivo VI: Delivery to the lung
32. Experience with liposomal amphotericin B (AmBisome) in cryptococcal meningitis in AIDS
33. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS
34. Successful treatment of cryptococcal meningitis with amphotericin B colloidal dispersion: Report of four cases
35. Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients
36. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis
37. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis
38. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients
39. Amphotericin B does not mix with fat emulsion
40. Successful treatment of fungal infections in neutropenic patients with liposomal amphotericin (AmBisome): A report on 40 cases from a single centre
41. Liposomal amphotericin B (AmBisome) therapy of invasive fungal infections: Evaluation of United Kingdom compassionate use data
42. Amphotericin B lipid complex to treat invasive fungal infections in cancer patients: Report of efficacy and safety in 20 patients
43. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients
44. An EORTC international multicenter randomized trial comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis
45. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America